Researchers Awarded $15 Million to Study Heart Valve Disease

The program is titled the Strategically Focused Research Network on Earlier Detection and Delaying Progression of Valvular Heart Disease, funded by the American Heart Association (AHA).

These networks aim to address core strategic issues identified by the AHA’s volunteer Board of Directors, spanning prevention, hypertension, heart failure, atrial fibrillation, obesity, vascular disease, cardiometabolic health, and other intersecting domains.

The emphasis is on understanding and improving early detection and prevention of progression in valvular heart disease.

• A new $15 million, four-year initiative will be led by scientific teams from Mass General Brigham Heart and Vascular Institute (Boston), Cincinnati Children’s Hospital Center, and the University of Pittsburgh.
• The project forms part of the AHA’s ongoing portfolio of Strategically Focused Research Networks, which collectively amount to roughly $300 million in investments across 19 networks since inception.
• The funding window for this network spans four years, beginning April 1, 2026, with collaborative research projects integrated across the three designated centers.

The condition affects a substantial global population, with estimates indicating more than 80 million people worldwide living with some form of valvular disease.

The condition is noted to become more prevalent with aging and can progress silently, often without early warning signs.

The authors emphasize that early identification of warning signs and timely diagnosis prior to symptom onset may broaden treatment options and mitigate complications.

• Heart valve disease is described as a common cardiovascular condition in which one or more heart valves fail to open properly or close completely, leading to altered blood flow with potential backward leakage.
• In the United States, valvular disease contributes to more than 57,000 deaths annually, according to the AHA’s 2026 Heart Disease and Stroke Statistics.
• The passage highlights the potential consequences of untreated disease, including heart failure, arrhythmias, recurrent hospitalizations, reduced quality of life, and premature death.

Rosen, M.D., FAHA, aligns with the network’s aims by underscoring the limited visibility of valvular disease and the emphasis on early detection.

Dr.

Rosen notes that the condition often lacks noticeable early warning signs and that damage may be advanced by the time symptoms arise, which justifies the focus on early detection and preventive strategies.

The new network is positioned as a way to extend impact earlier through innovative, cutting-edge investigations.

• A quote from Stacey E.
• The AHA frames heart valve disease as a priority area and references related initiatives, including its Heart Valve Initiative and the Target: Aortic Stenosis quality improvement program, as existing mechanisms to improve patient care from a clinical systems perspective.

The structure envisions 3 to 6 centers per network, with investigators contributing expertise across disciplines to advance diagnosis, treatment, and prevention of valvular heart disease.

The approach implies a mix of translational work, observational studies, and potentially interventional concepts aimed at improving diagnostic accuracy and delaying disease advancement, though specific study designs or interventions are not enumerated in the source content.

• The three lead centers (Mass General Brigham Heart and Vascular Institute, Cincinnati Children’s Hospital Medical Center, and the University of Pittsburgh) will coordinate multi-center research efforts that span basic, clinical, and population/behavioral science domains.
• Projects within the network are described as collaborative and cross-center, with an emphasis on early detection and the delaying progression of valvular disease.

The initiative is presented as a pathway to generate new scientific knowledge that could translate into improved diagnostic and preventive strategies.

• The network aligns with a broader objective to fill knowledge gaps related to early diagnosis, progression, and intervention opportunities for valvular heart disease.
• The description indicates that prior AHA networks have pursued a diversity of topics, including prevention, hypertension, women’s health, heart failure, obesity, vascular disease, arrhythmias, inflammation, and cardio-metabolic health, illustrating the organization’s longstanding emphasis on comprehensive cardiovascular health research.

This contextualizes the scale and mission of the current initiative within a wider philanthropic and scholarly framework.

adults express confidence in the AHA as a source of trustworthy public health information, underscoring the organization’s role in public health messaging and community trust, which complements the research investment approach.

• The AHA has historically funded substantial investment in cardiovascular, cerebrovascular, and brain health research, exceeding $6.1 billion since 1949 through its networked and other research funding mechanisms.
• The article notes that more than 8 in 10 U.S.

Hilaire, Ph.D., FAHA, director of the Center for Integrative Valve Science and associate professor of medicine at the University of Pittsburgh.

• The article identifies three principal investigators who will participate in leadership roles across the collaborating centers:
• Andrea Beaton, M.D., M.S., FAHA, a professor of pediatrics at the University of Cincinnati and pediatric cardiologist at Cincinnati Children's Hospital Medical Center.
• Elena Aikawa, M.D., Ph.D., FAHA, director of the Heart Valve Translational Research Program at Brigham and Women’s (Mass General Brigham) in Boston.
• Cynthia St.
• These individuals are presented as key figures linking pediatric, translational valve science, and integrative approaches to valve disease research.

The content does not specify inclusion criteria, population sizes, or geographic distribution of the participating centers beyond the three named institutions.

• The source provides a broad overview of the network and its funding, but lacks specific details on study designs, expected endpoints, or precise diagnostic or therapeutic targets within the scope of early detection and progression delay for valvular disease.
• No numerical outcomes, projected timelines for individual studies within the network, or interim results are reported.
• While the article underscores the global burden of valvular disease and its clinical consequences, it does not present data on the prevalence by valve type, etiologies, or risk stratification models that might guide research questions.

• The initiative is framed as an important step toward improving early identification of valvular disease and delaying progression, with the expectation that outcomes from the funded projects could inform practice patterns and health-system approaches as the research unfolds.